Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
CRCL
MCID: CRT084
MIFTS: 25

Creatinine Clearance Quantitative Trait Locus (CRCL)

Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Creatinine Clearance Quantitative Trait Locus

About this section

MalaCards integrated aliases for Creatinine Clearance Quantitative Trait Locus:

Name: Creatinine Clearance Quantitative Trait Locus 56
Creatinine Clearance Qtl 56 13
Crcl 56

External Ids:

OMIM 56 607135
Sources

Summaries for Creatinine Clearance Quantitative Trait Locus

About this section
MalaCards based summary : Creatinine Clearance Quantitative Trait Locus, also known as creatinine clearance qtl, is related to glioblastoma multiforme and rapidly involuting congenital hemangioma. An important gene associated with Creatinine Clearance Quantitative Trait Locus is CRCL (Creatinine Clearance QTL). The drugs Valganciclovir and Colchicine have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and liver.

More information from OMIM: 607135
Sources

Related Diseases for Creatinine Clearance Quantitative Trait Locus

About this section

Diseases related to Creatinine Clearance Quantitative Trait Locus via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 glioblastoma multiforme 10.3
2 rapidly involuting congenital hemangioma 10.3
3 ovarian cancer 10.2
4 ataxia and polyneuropathy, adult-onset 10.2
5 chagas disease 10.2
6 mouth disease 10.2
7 pathologic nystagmus 10.2

Graphical network of the top 20 diseases related to Creatinine Clearance Quantitative Trait Locus:



Diseases related to Creatinine Clearance Quantitative Trait Locus
Sources

Symptoms & Phenotypes for Creatinine Clearance Quantitative Trait Locus

About this section

Clinical features from OMIM:

607135
Sources

Drugs & Therapeutics for Creatinine Clearance Quantitative Trait Locus

About this section

Drugs for Creatinine Clearance Quantitative Trait Locus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 296)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Valganciclovir Approved, Investigational Phase 4 175865-60-8 64147
2
Colchicine Approved Phase 4 64-86-8 6167 2833
3
Dalteparin Approved Phase 4 9005-49-6
4
Fondaparinux Approved, Investigational Phase 4 104993-28-4
5
Ribavirin Approved Phase 4 36791-04-5 37542
6
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
7
Iron Approved, Experimental Phase 4 7439-89-6, 15438-31-0 23925 27284
8
Warfarin Approved Phase 4 81-81-2 6691 54678486
9
Rivaroxaban Approved Phase 4 366789-02-8
10
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
11
Edoxaban Approved Phase 4 480449-70-5
12
Enoxaparin Approved Phase 4 9005-49-6 772
13
Pemetrexed Approved, Investigational Phase 4 150399-23-8, 137281-23-3 446556 60843
14
Phylloquinone Approved, Investigational Phase 4 84-80-0
15
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
16
Procaine Approved, Investigational, Vet_approved Phase 4 59-46-1 4914
17
Penicillin G Approved, Vet_approved Phase 4 61-33-6 5904
18
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
19
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
20
Acetaminophen Approved Phase 4 103-90-2 1983
21
Hydrocodone Approved, Illicit, Investigational Phase 4 125-29-1 5284569
22
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
23
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
24
Morphine Approved, Investigational Phase 4 57-27-2 5288826
25
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
26
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
27
Ceftaroline fosamil Approved, Investigational Phase 4 229016-73-3
28
Linezolid Approved, Investigational Phase 4 165800-03-3 441401
29
Daptomycin Approved, Investigational Phase 4 103060-53-3 16129629
30
Vancomycin Approved Phase 4 1404-90-6 441141 14969
31
Fosfomycin Approved Phase 4 23155-02-4 446987
32
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
33
Ofloxacin Approved Phase 4 82419-36-1 4583
34
Creatine Approved, Investigational, Nutraceutical Phase 4 57-00-1 586
35
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
36
Dabigatran Investigational Phase 4 211914-51-1
37 Menaquinone Investigational Phase 4 1182-68-9
38 Heparin, Low-Molecular-Weight Phase 4
39 PENTA Phase 4
40 Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Phase 4
41 interferons Phase 4
42 Interferon-alpha Phase 4
43 Hematinics Phase 4
44 Ferric Oxide, Saccharated Phase 4
45 Calamus Phase 4
46 Fibrinolytic Agents Phase 4
47 Platelet Aggregation Inhibitors Phase 4
48 Antithrombins Phase 4
49 Serine Proteinase Inhibitors Phase 4
50 Anticoagulants Phase 4

Interventional clinical trials:

(show top 50) (show all 118)
# Name Status NCT ID Phase Drugs
1 Single-Dose, Open-Label Study of the Pharmacokinetics, Safety, and Tolerability of Colcrys (Colchicine, USP) Tablets 0.6 mg Administered to Healthy Subjects and Subjects With Mild, Moderate, Severe Renal Impairment, and End-Stage Renal Disease Completed NCT01084278 Phase 4 Colchicine
2 Prospective, Multicentre, Open-label Study Evaluating 1.5 mg/Day of Fondaparinux,in Venous Thromboembolic Events Prevention in Patients With Renal Impairment and Undergoing a Major Orthopaedic Surgery. PROPICE Study Completed NCT00555438 Phase 4 fondaparinux 1.5 mg/day
3 A Prospective, Open Label Study to Evaluate the Pharmacokinetics of Dabigatran in Non-valvular Atrial Fibrillation (NVAF) Patients With Severely Impaired Renal Function on Dabigatran Etexilate 75 mg BID Therapy Completed NCT01896297 Phase 4 Pradaxa, dabigatran etexilate
4 Individualization of Ganciclovir and Valganciclovir Doses in Renal Transplant Patients for Prophylaxis or Treatment of Cytomegalovirus(CMV)Infection Using Bayesian Prediction. Completed NCT01446445 Phase 4 Ganciclovir/ Valganciclovir according to SPC;Ganciclovir/ Valganciclovir according to PK model
5 A Pilot Demonstration Project to Operationalize Pre-exposure Prophylaxis as Part of Combination HIV Prevention Among Men Who Have Sex With Men (MSM) and Transgender Women in Los Angeles County Completed NCT01781806 Phase 4 emtricitabine 200mg/tenofovir 300mg
6 Non-Randomized, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Peginterferon Alfa-2a and Copegus Combination Therapy After Single and Multiple Doses in Patients With Chronic Hepatitis C and Moderate Renal Impairment, Severe Renal Impairment, or End-Stage Renal Disease Undergoing Hemodialysis Completed NCT02864199 Phase 4 Peginterferon alfa-2a;Ribavirin
7 Use of Dabigatran Etexilate to Prevent Stroke and Thromboembolism in Patients Undergoing Left Atrial Catheter Ablation Procedures for Paroxysmal or Persistent (Non-permanent) Atrial Fibrillation and Left Atrial Flutter Completed NCT01976507 Phase 4 dabigatran etexilate mesylate
8 Valganciclovir Dosing in Pediatric Solid Organ Transplant Recipients - a Prospective Study Completed NCT02503982 Phase 4 prophylactic Valganciclovir
9 Immediate Versus Deferred Antiretroviral Therapy in HIV-infected Patients Presenting With Acute AIDS-defining Events (IDEAL-Study) Completed NCT01417949 Phase 4
10 Hospitalization and Mortality in Iron Deficient, Anemic Patients With Chronic Kidney (CKD) and Heart Failure Receiving Intravenous Iron Therapy: A Five Year Follow-up From a Pilot Study Completed NCT02392910 Phase 4 Iron Sucrose;Placebo
11 Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation (CAF Trial) Recruiting NCT03061006 Phase 4 Dabigatran Etexilate;Warfarin
12 A Multi-centre, Open-labelled, Randomized Controlled Trial Comparing Two Different Anticoagulation Strategies in High-risk Atrial Fibrillation and Stable Coronary Artery Disease Recruiting NCT03718559 Phase 4 Edoxaban;Single Antiplatelet Agents
13 Pemetrexed in Maintenance in Patients With Impaired Renal Function: Randomized Phase 4 Multicenter Study Comparing 2 Dose Calculation Strategies (PKAPIR) Recruiting NCT03607149 Phase 4 Pemetrexed
14 A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure Recruiting NCT03088072 Phase 4 Edoxaban;Aspirin and Clopidogrel;Aspirin and Warfarin
15 Rivaroxaban Once Daily Versus Dose-adjusted Vitamin K Antagonist on the Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF) Recruiting NCT03490994 Phase 4 Rivaroxaban;Warfarin + LMWH
16 Pilot Randomised Controlled Trial of Penicillin Versus Flucloxacillin for Definitive Treatment of Invasive Penicillin Susceptible Staphylococcus Aureus Not yet recruiting NCT03632642 Phase 4 Benzylpenicillin;Flucloxacillin
17 Evaluation of Intravenous Glucocorticoid Therapy in Total Knee Arthroplasty Suspended NCT02219581 Phase 4 Dexamethasone 10 mg;Dexamethasone 20 mg;Standard multimodal pain management regimen;Placebo
18 Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients Terminated NCT01734694 Phase 4 Vancomycin;Ceftaroline;Daptomycin;Linezolid
19 Multi-center, Randomized, Open-label Trial to Evaluate the Efficacy of Oral Fosfomycin Versus Oral Levofloxacin Strategies in Complicated Urinary Tract Infections (FOCUS) Terminated NCT03697993 Phase 4 Fosfomycin tromethamine;Levofloxacin
20 Prospective Evaluation of a Vancomycin Nomogram With a Continuous Infusion of Vancomycin for Surgical ICU Patients Terminated NCT01786161 Phase 4 Vancomycin continuous infusion;Vancomycin intermittent dosing interval
21 Phase IV Study of the Outpatient Treatment of Gram Positive Wound Infections in the Diabetic Foot: A Pharmaco-Economic Comparison of Daptomycin vs Vancomycin Based Regimens Terminated NCT01133600 Phase 4 Cubicin;Vancomycin
22 Prospective, Multi-center, Open-label, Phase IV Study to Evaluate the Safety and Efficacy of Alogliptin as Monotherapy or Add on Therapy in Indian Patients With Type 2 Diabetes Mellitus Withdrawn NCT03042325 Phase 4 Alogliptin
23 To Evaluate the Renal Tubular Function Pre and Post Nephrectomy in Living Donors Withdrawn NCT03676361 Phase 4 Desmopressin
24 Thromboprophylaxis in Patients Undergoing Orthopedic Surgeries; Focus on Cost-effective Analysis and Safety Comparison Between Rivaroxaban and Enoxaparin Unknown status NCT03299296 Phase 3 Rivaroxaban 10 Milligrams;Enoxaparin 40 Milligrams/0.4 Milliliters Prefilled Syringe
25 International Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of KIACTA in Preventing Renal Function Decline in Patients With AA Amyloidosis Completed NCT01215747 Phase 3 KIACTA (eprodisate disodium);Placebo
26 Evaluation of the Efficacy and Safety of Rivaroxaban (BAY59-7939) for the Prevention of Stroke and Non-central Nervous System Systemic Embolism in Subjects With Non-valvular Atrial Fibrillation Completed NCT00494871 Phase 3 Rivaroxaban (Xarelto, BAY59-7939);Warfarin;Rivaroxaban placebo;Warfarin placebo
27 Safety and Pharmacokinetics of Valganciclovir Syrup Formulation in Pediatric Solid Organ Transplant Recipients Completed NCT00090766 Phase 2, Phase 3 valganciclovir [Valcyte]
28 A Phase 3, Multicenter, Randomized, Openlabel, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid®) Versus Chlorambucil as First-Line Therapy for Previously Untreated Elderly Patients With B-Cell Chronic Lymphocytic Leukemia (The Origin Trial) Completed NCT00910910 Phase 3 Lenalidomide;Chlorambucil
29 An Open-label, International, Multicenter, Interventional Study Exploring the Efficacy of Once-daily Oral Rivaroxaban (BAY 59-7939) for the Treatment of Left Atrial/Left Atrial Appendage Thrombus in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter Completed NCT01839357 Phase 3 Rivaroxaban (Xarelto, BAY59-7939)
30 A Prospective, Randomized, Open-label, Parallel-group, Active-controlled, Multicenter Study Exploring the Efficacy and Safety of Once-daily Oral Rivaroxaban (BAY59-7939) Compared With That of Dose-adjusted Oral Vitamin K Antagonists (VKA) for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion Completed NCT01674647 Phase 3 Rivaroxaban (Xarelto, BAY59-7939);Vitamin K antagonist (VKA)
31 A Phase 3, Multicenter, Double-blind, Randomized, Active-controlled Clinical Study to Evaluate the Efficacy and Safety of Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem in Chinese Participants With Complicated Intra-abdominal Infection Recruiting NCT03830333 Phase 3 Ceftolozane/Tazobactam;Metronidazole;Meropenem;Placebo
32 Effects of Fenofibrate Administration in Patients With Diabetic Nephropathy Recruiting NCT03869931 Phase 3 Fenofibrate
33 Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes - An Investigator-driven, Prospective, Randomised, Double-blind, Multi-centre Trial Initiated by the European Society of Cardiology and AFNET Recruiting NCT02618577 Phase 3 Edoxaban;ASA
34 Apixaban Versus Warfarin in Patients With Left Ventricular (LV) Thrombus Recruiting NCT03232398 Phase 3 Apixaban Oral Tablet [Eliquis];Warfarin
35 A Randomized, Open Label, Active Control, 2 Parallel Groups, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Balanced Salt Solution Versus 0.9% Saline in Patients With High Risk of Contrast Induced Nephropathy. Recruiting NCT02799368 Phase 3 CJ Plasma Solution A Injection;CJ 0.9% Normal Saline Injection
36 COMPARE: Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Patients With Multiple Myeloma Terminated NCT02739594 Phase 3 Ibandronate;Zoledronate
37 Phase II Clinical Study Of An Individualized Anti-Cancer Vaccine (CRCL-ALLOVAX) in Subjects With Advanced Hepatocellular Carcinoma Unknown status NCT02409524 Phase 2
38 Phase I/II, Randomized Double-Blinded, Placebo-Controlled Study Designed To Evaluate Safety, Tolerability of an Individualized Cancer Vaccine (AllovaxTM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck. Unknown status NCT01998542 Phase 1, Phase 2
39 An Individualized Cancer Vaccine for Recurrent/Metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (SCCHN) Unknown status NCT02624999 Phase 2 Cisplatin
40 A Phase IIb Trial of Vorinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma Patients Refractory to Previous Lenalidomide Containing Regimens Unknown status NCT01502085 Phase 1, Phase 2 Vorinostat, Lenalinomide and Dexamethasone
41 Phase II Trial Investigating Tailoring First-Line Therapy For Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma Based on Mid-Treatment Positron Emission Tomography (PET) Scan Results Unknown status NCT00324467 Phase 2 Cyclophosphamide;Doxorubicin;Vincristine;Prednisone;Ondansetron;Dexamethasone;Diphenhydramine;Acetaminophen;Ifosfamide;Mesna (IV);Mesna (oral);Carboplatin;Etoposide;Rituximab;Ondansetron;Dexamethasone;Diphenhydramine;Acetaminophen
42 Phase II Study of the Combination of Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis Completed NCT01222260 Phase 2 Bendamustine;Dexamethasone
43 N-acetylcysteine and Fenoldopam Protect the Renal Function of Patients With Chronic Renal Insufficiency Undergoing Cardiac Surgery. Completed NCT00122018 Phase 2 N-acetylcysteine;fenoldopam
44 A Multicenter, Double-blind, Randomized, Clinical Study to Assess the Efficacy and Safety of Intravenous S-649266 in Complicated Urinary Tract Infections With or Without Pyelonephritis or Acute Uncomplicated Pyelonephritis Caused by Gram-Negative Pathogens in Hospitalized Adults in Comparison With Intravenous Imipenem/Cilastatin Completed NCT02321800 Phase 2 Cefiderocol;Imipenem/cilastatin
45 An Open-label, Pharmacokinetic Study of Lenalidomide (Revlimid) and High-dose Dexamethasone Induction Therapy in Previously Untreated Multiple Myeloma Patients With Various Degrees of Renal Dysfunction - Validation of Official Dosing Guidelines for Renal Failure Completed NCT01270932 Phase 2 Lenalidomide and Dexamethasone
46 Low Intensity Allogeneic Hematopoietic Stem Cell Transplantation Therapy of Metastatic Renal Cell Carcinoma Using Early and Multiple Donor Lymphocyte Infusions Consisting of Sirolimus-Generated Donor Th2 Cells Completed NCT00923845 Phase 2 Pentostatin;Sirolimus;Cyclophosphamide
47 The Impact of Bisphosphonates on Bone Loss in Patients Undergoing Surgery and Postoperative Chemotherapy for Gynecologic Malignancies. Completed NCT00593580 Phase 2 placebo;alendronate/cholecalciferol
48 Dipeptidyl Peptidase-4 Inhibition and Narrow-band Ultraviolet-B Light in Psoriasis (DINUP): A Randomised Clinical Trial Completed NCT02347501 Phase 2 Sitagliptin (Januvia)
49 Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial. Completed NCT01991197 Phase 2 Sitagliptin;Gliclazide;Sitagliptin matched placebo;Gliclazide matched placebo capsule
50 Phase 2 Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations Recruiting NCT03448718 Phase 2 Olaparib

Search NIH Clinical Center for Creatinine Clearance Quantitative Trait Locus

Sources

Genetic Tests for Creatinine Clearance Quantitative Trait Locus

About this section
Sources

Anatomical Context for Creatinine Clearance Quantitative Trait Locus

About this section

MalaCards organs/tissues related to Creatinine Clearance Quantitative Trait Locus:

40
Kidney, Heart, Liver, Bone, Lung, Skin, Testes
Sources

Publications for Creatinine Clearance Quantitative Trait Locus

About this section

Articles related to Creatinine Clearance Quantitative Trait Locus:

(show top 50) (show all 1479)
# Title Authors PMID Year
1
A genome scan for renal function among hypertensives: the HyperGEN study. 56
11115379 2001
2
Simultaneous reduction of nitrate and Cr(VI) by Pseudomonas aeruginosa strain G12 in wastewater. 61
31812281 2020
3
Population Pharmacokinetics of High-Dose Methotrexate in Chinese Pediatric Patients with Medulloblastoma. 61
32017134 2020
4
Population pharmacokinetic model of Vancomycin based on therapeutic drug monitoring data in critically ill septic patients. 61
31715528 2020
5
Preventive Effects of Nicorandil Against Contrast-Induced Nephropathy in Patients With Moderate Renal Insufficiency Undergoing Percutaneous Coronary Intervention. 61
30987432 2020
6
Monte Carlo Simulation Methodologies for β-Lactam/β-Lactamase Inhibitor Combinations: Effect on Probability of Target Attainment Assessments. 61
31423601 2020
7
Safety outcomes of apixaban in patients with nonvalvular atrial fibrillation and severe renal impairment. 61
31902123 2020
8
The effect of tibial plateau leveling osteotomy on patellofemoral kinematics in dogs: An in vivo study. 61
31373719 2020
9
Recommendations for rehabilitation after surgical treatment of cranial cruciate ligament disease in dogs: A 2017 survey of veterinary practitioners. 61
31390083 2020
10
Average Tibial Plateau Angle of 3,922 Stifles Undergoing Surgical Stabilization for Cranial Cruciate Ligament Rupture. 61
31978937 2020
11
Impact of Severity of Chronic Kidney Disease on Management and Outcomes Following Transcatheter Aortic Valve Replacement With Newer-Generation Transcatheter Valves. 61
31841995 2020
12
Thermochemical formation of dioxins promoted by chromium chloride: In situ Cr- and Cl-XAFS analysis. 61
31954297 2020
13
Relationship between the Renal Function and Adverse Clinical Events in Patients with Atrial Fibrillation: A Japanese Multicenter Registry Substudy. 61
31936260 2020
14
Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation. 61
31911503 2020
15
Effect of TDF-containing regimens on creatinine clearance in HIV patients in Namibia with a baseline CrCl <60ml/min; findings and implications. 61
31829065 2020
16
Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urate-Lowering Response-In Search of a Minimum Effective Oxypurinol Concentration. 61
31444839 2020
17
Chromium complexes bearing disubstituted organophosphate ligands and their use in ethylene polymerization. 61
31919312 2020
18
Pretransplant hemoglobin and creatinine clearance correlate with treatment-free survival after autologous stem cell transplantation for multiple myeloma. 61
31388085 2019
19
Pharmacokinetics of Telavancin in Adult Patients with Cystic Fibrosis during Acute Pulmonary Exacerbation. 61
31685468 2019
20
Correlation between orthopaedic and radiographic examination findings and arthroscopic ligament fibre damage in dogs with cruciate ligament rupture. 61
31565798 2019
21
Determining the phase diagram of atomically thin layered antiferromagnet CrCl3. 61
31712666 2019
22
Population Pharmacokinetics of Milrinone in Infants, Children, and Adolescents. 61
31317556 2019
23
Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience. 61
31473974 2019
24
Effect of angiotensin receptor blockers on blood pressure and renal function in patients with concomitant hypertension and chronic kidney disease: a systematic review and meta-analysis. 61
31392910 2019
25
Efficacy and safety of the new antiviral agents for the treatment of hepatitis C virus infection in Egyptian renal transplant recipients. 61
31531807 2019
26
Real-life behaviour of direct oral anticoagulants in a Spanish cohort with non-valvular atrial fibrillation: Refase Registry. 61
31335222 2019
27
Once-Daily versus Twice-Daily Tacrolimus in Kidney Transplantation: A Systematic Review and Meta-analysis of Observational Studies. 61
31713065 2019
28
Risk Factors and Outcomes Associated with Prolonged Subtherapeutic Anticoagulation with Bivalirudin: A Retrospective Cohort Study. 61
31587337 2019
29
[Anticoagulation in patients with non-valvular atrial fibrillation (nvAF) and chronic kidney disease (CKD)]. 61
31752037 2019
30
2D CrCl2(pyrazine)2 monolayer: high-temperature ferromagnetism and half-metallicity. 61
31778979 2019
31
Tinzaparin Sodium Pharmacokinetics in Patients with Chronic Kidney Disease: Practical Implications. 61
31721053 2019
32
Worsening renal function, adverse clinical events and major determinants for changes of renal function in patients with atrial fibrillation: a Japanese multicenter registry substudy. 61
31204852 2019
33
Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation and chronic kidney disease. 61
31599969 2019
34
Real-world 2-year outcome of atrial fibrillation treatment with dabigatran, apixaban, and rivaroxaban in patients with and without chronic kidney disease. 61
31073827 2019
35
Investigating subtle kidney injury in primary hyperparathyroidism by means of sensitive and specific biomarkers. 61
31309599 2019
36
Effectiveness of Methenamine for UTI Prevention in Older Adults. 61
31694390 2019
37
Millimeter/sub-mm spectroscopy of the CrBr radical in the high spin X6Σ+ state. 61
31757148 2019
38
Clinical risk factors of stroke and major bleeding in patients with non-valvular atrial fibrillation under rivaroxaban: the EXPAND Study sub-analysis. 61
31127325 2019
39
Preparation of Ganoderma lucidum polysaccharide‑chromium (III) complex and its hypoglycemic and hypolipidemic activities in high-fat and high-fructose diet-induced pre-diabetic mice. 61
31401268 2019
40
Chromium(II)-Catalyzed Diastereoselective and Chemoselective Csp2-Csp3 Cross-Couplings Using Organomagnesium Reagents. 61
31634428 2019
41
Factors related to inappropriate edoxaban use. 61
31292978 2019
42
Analysis of carboplatin dosing in patients with a glomerular filtration rate greater than 125 mL/min: To cap or not to cap? A retrospective analysis and review. 61
30336729 2019
43
Evaluation of the Accuracy of Standard Renal Function Equations in Critically Ill Patients with Subarachnoid Hemorrhage. 61
31591691 2019
44
Creatinine monitoring patterns in the setting of direct oral anticoagulant therapy for non-valvular atrial fibrillation. 61
31111434 2019
45
Is serum uric acid a predictor of long-term renal outcome in lupus nephritis? 61
31154554 2019
46
Cefoperazone/sulbactam therapeutic drug monitoring in patients with liver cirrhosis: Potential factors affecting the pharmacokinetic/pharmacodynamic target attainment. 61
31056857 2019
47
Real-world outcomes of rivaroxaban treatment in elderly Japanese patients with nonvalvular atrial fibrillation. 61
31492970 2019
48
Rates and risk factors for nephrotoxicity and ototoxicity among tuberculosis patients in Tbilisi, Georgia. 61
31615608 2019
49
Toxicity and effectiveness of carboplatin in obese or overweight patients. 61
30086680 2019
50
Cu(i), Ag(i), Ni(ii), Cr(iii) and Ir(i) complexes with tritopic NimineCNHCNamine pincer ligands and catalytic ethylene oligomerization. 61
31389452 2019
Sources

Variations for Creatinine Clearance Quantitative Trait Locus

About this section
Sources

Expression for Creatinine Clearance Quantitative Trait Locus

About this section
Search GEO for disease gene expression data for Creatinine Clearance Quantitative Trait Locus.
Sources

Pathways for Creatinine Clearance Quantitative Trait Locus

About this section
Sources

GO Terms for Creatinine Clearance Quantitative Trait Locus

About this section
Sources

Sources for Creatinine Clearance Quantitative Trait Locus

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....